Inappropriate prescribing in the hospitalized elderly patient: Defining the problem, evaluation tools, and possible solutions

Robert L Page II¹
Sunny A Linnebur²
Lucinda L Bryant³
J Mark Ruscini⁴

¹Associate Professor of Clinical Pharmacy and Physical Medicine, Clinical Specialist, Division of Cardiology and Heart Transplantation,

²Associate Professor of Clinical Pharmacy, Clinical Specialist, Center on the Aging, Schools of Pharmacy and Medicine, ³Assistant Professor of Community and Behavioral Health, Colorado School of Public Health, University of Colorado Denver, Aurora, CO, USA; ⁴Professor, Department of Pharmacy Practice, Southern Illinois University Edwardsville School of Pharmacy, Edwardsville, IL, USA

Abstract: Potentially inappropriate medication (PIM) prescribing in older adults is quite prevalent and is associated with an increased risk for adverse drug events, morbidity, and utilization of health care resources. In the acute care setting, PIM prescribing can be even more problematic due to multiple physicians and specialists who may be prescribing for a single patient as well as difficulty with medication reconciliation at transitions and limitations imposed by hospital formularies. This article highlights critical issues surrounding PIM prescribing in the acute care setting such as risk factors, screening tools, and potential strategies to minimize this significant public health problem.

Keywords: inappropriate prescribing, aged, elderly, adverse drug events, adverse drug reactions, Beers' criteria, screening

The medication-use process is a complicated progression of steps traditionally consisting of prescribing, communicating orders, dispensing, administering, and monitoring.¹ At each step, the potential for associated health risks exist; however, many preventable problems can occur at the initial prescribing stage.¹ While no set definition has been established, inappropriate prescribing encompasses the use of medications that introduce a significant risk of an adverse drug event (ADE) when there exists evidence for an equally or more effective but lower-risk alternative therapy for treating the same medical condition.² Additional situations also include over-use of medications at a higher frequency or for longer durations than clinically indicated, under-use of medically indicated medications based on ageist or irrational reasons, and use of multiple medications that have documented drug–drug interactions or drug–disease interactions.^{1,2}

It is no surprise that inappropriate prescribing commonly occurs in adults aged 65 years or older, who have a higher prevalence of chronic disease, disability, and dependency than younger adults.³ While only 13% of Americans are aged 65 years or older, this group represents the largest per capita consumers of prescription medications.^{4,5} A recent survey of 3,500 community-dwelling adults found that over 29% take five or more prescription medications, 42% at least one or more over-the-counter medications, and 49% at least one or more dietary supplements.⁴ With increasing life expectancy, improved prescription drug coverage through the implementation of the Medicare Part D Prescription Drug Benefit Plan, and the emergence of over 50 new drugs per year into the United States (US) market, it seems likely that consumption of prescription drugs by older adults will continue to increase. Additionally, the continued development of life saving and lifestyle-saving medications, as well as direct to consumer marketing,

Correspondence: Robert Lee Page II
Associate Professor of Clinical Pharmacy and Physical Medicine, Clinical Specialist, Cardiology, University of Colorado, School of Pharmacy and Medicine, C238-L15, Academic Office I, 12631 East 17th Ave, Room L15-1415, PO Box 6511, Aurora, CO 80045, USA
Tel +1 303 724 2626
Fax +1 303 724 2627
Email robert.page@ucdenver.edu

seems to have created an excess dependence on medication therapy to solve everyday problems.

A number of studies have documented that potentially inappropriate medication (PIM) prescribing in older adults is common in the ambulatory setting, nursing homes, and the emergency department and that exposure to inappropriate medications is associated with increased morbidity, mortality, health care resource utilization, and ADEs.⁵ However, limited data exist regarding PIM prescribing in the acute care setting, although adults aged 65 years or older account for over 35% of annual hospital admissions.^{6–10} Older adults are also at increased risk for hospital readmission. An analysis of fee for service Medicare beneficiaries found that 19.6% of patients who had been discharged from a hospital were rehospitalized within 30 days, and 34.0% were rehospitalized within 90 days.¹¹ Of note, the hospital environment can be particularly perilous for older adults. Hospitalization has been associated with a higher incidence of adverse outcomes including functional decline, delirium, and falls as well as ADEs in this population.^{12,13} A meta-analysis of 39 studies found an in-hospital incidence of ADEs of 6.7% and an incidence of fatal ADEs of 0.3%, which may be slightly higher than what has been documented in the outpatient setting.^{14,15} Furthermore, older adults in the inpatient setting may be exposed to new and possibly unnecessary medications, multiple providers and specialists, and restrictive hospital formularies that require reconciliation with home medications; all of these can increase the risk for PIM prescribing.^{16,17}

In order to address this public health concern in older adults, particularly within the hospital environment, it is crucial that clinicians have an understanding of potential risk factors for PIM prescribing, advantages and limitations of validated drug evaluation tools for identifying PIM prescribing, and possible strategic approaches to curtailing the problem.

Risk factors for PIM prescribing

No research has yet identified clear risk factors specific to PIM prescribing in the hospitalized older adult, but it may be possible to extrapolate from an evaluation of the root causes for ADEs to develop a potential list. Data in hospitalized patients suggest that advanced age (≥ 85 years), polypharmacy, and number of comorbidities can contribute to an increased likelihood of ADEs.^{18–21}

Advanced age

While complex issues surrounding frailty, social and emotional infrastructure, and economic status can influence

inappropriate prescribing, the major impact of advanced age lies in the context of altered pharmacokinetics (drug absorption, distribution, metabolism and excretion), altered pharmacodynamics (physiological effects of the drug) and age-related changes in body composition and physiology. With advanced age, lean body mass and total body water decrease, with a relative increase in total body fat. Such changes lead to a decreased volume of distribution for hydrophilic, narrow therapeutic drugs such as lithium and digoxin for which unadjusted dosing can result in higher plasma concentrations and possible toxicity. Conversely, lipid-soluble drugs such as long-acting benzodiazepines have an increased volume of distribution, thereby delaying their immediate effects and resulting in potentially dangerous accumulation with continued use.²²

Advanced age is also associated with a reduction in hepatic mass and blood flow. Drugs such as beta-blockers, nitrates, and tricyclic antidepressants (TCAs) that exhibit significant hepatic first pass metabolism may have a higher bioavailability and faster onset, which will warrant initiation at lower doses with possible extended administration intervals. Cytochrome P450 oxidation also declines, increasing the risk for toxicity and possible drug – drug interactions for drugs that are substrates of these enzymes.²³ With aging also come associated changes in renal structure and subsequent altered drug excretion. Drug dosages eliminated via the kidneys should be adjusted for compromised renal function. If serum albumin is decreased, the active unbound drug concentration will increase for highly protein-bound narrow therapeutic drugs such as phenytoin, theophylline, warfarin, and digoxin.

Finally, aging is also associated with changes in the end-organ responsiveness to drugs at receptor or post-receptor levels. There is decreased sensitivity to beta-receptors along with a possible decreased clinical response to beta-blockers and beta-agonists. The central nervous system becomes more vulnerable in the elderly to agents that affect brain function (eg, opioids, benzodiazepines, and psychotropic drugs).²⁴

Polypharmacy

While treatment of multiple chronic diseases may justify the use of several drugs concomitantly, polypharmacy is associated with an increased risk for ADEs as well as drug-drug and drug-disease interactions.²⁵ Goldberg and colleagues found that patients taking two drugs face a 13% risk of adverse drug-drug interactions, rising to 38% for four drugs and to 82% if seven or more drugs are given simultaneously.²⁶ Duplicate prescribing within the same drug class is prevalent

and frequently unrecognized.^{25,26} ADEs are often treated with additional drugs, leading to prescribing cascades.²⁵ Polypharmacy can also augment the risk for medication non-adherence, which in turn can lead to suboptimal therapeutic effectiveness and poor clinical consequences.²⁷ If providers do not recognize the existence of medication nonadherence, they may increase the dose of the initial medication or add a second agent, increasing not only the cost of therapy but risk for an ADE. It is clear that the use of multiple medications is associated with an increase in the risk of ADEs. However, the use of specific medications, such as atypical and typical antipsychotics as well as benzodiazepines should be of particular concern as well, as these medications are associated with decreased patient functioning and increased morbidity and mortality.^{3,28–30}

Multiple comorbidities

Among adults aged over 65 years, 84% present with two or more chronic conditions, compared with 35% of patients aged 45 to 65 years.³¹ Data have shown that having three or more comorbidities can increase the risk for having a severe ADE by 2.9–12.6-fold.²⁰ The pervasiveness of comorbidity is especially apparent in hospitals. In the hospital setting, 60% of inpatients had at least one comorbidity, and 37% had two or more.³² The leading comorbidities were hypertension (29.4%), chronic obstructive lung disease (COPD) (12.1%), diabetes mellitus (11.8%), fluid/electrolyte disorders (11.7%), iron deficiency/anemia (7.9%), and heart failure (5.7%). With each comorbidity comes additional exposure to a larger number of medications as well as new prescribers and specialists.³² For example, a Medicare beneficiary with heart failure may see on average 15–23 different providers within a given year.³³ In this scenario, communication between providers, flawless transitions of care, and the overall coordination of care are crucial, as failure in any of these steps could lead to duplication of medications, prescribing of unnecessary medications, and drug – drug interactions.

Validated drug utilization review tools

Appropriateness of prescribing can be assessed by process or outcome measures that are explicit (criterion-based) or implicit (judgment-based).⁵ Explicit indicators are usually developed from published reviews, expert opinions, and consensus techniques. These measures are usually drug or disease oriented and can be applied with little or no clinical judgment. Unfortunately, explicit criteria may not take into account all quality indicators of health care as defined

by national guidelines for an individual patient and their preferences, nor do they address the burden of comorbid conditions. In implicit approaches, a clinician employs patient-specific information and published evidence to form judgments about appropriateness. The focus is placed on the patient rather than on drugs or diseases. Implicit approaches are potentially more sensitive and can account for patients' preferences, but they are time-consuming, depend on the users' knowledge and attitudes, and can have low reliability. While no ideal measure exists, the strengths and weaknesses of both approaches should be taken into account. Presently, four tools exist to evaluate PIM prescribing in older adults.⁵ The Beers' Criteria, Improved Prescribing in the Elderly Tool (IPET), and Screening Tool of Older Persons (STOPP) are explicit approaches, while the Medication Appropriateness Index (MAI) is an implicit model.

The Beers' criteria

In 1991, Beers and colleagues published the first set of explicit criteria for determining PIM use in nursing home residents.³⁴ Based on consensus opinion from experts in geriatric medicine, long-term care, geriatric and psychogeriatric pharmacology and pharmacoepidemiology, they devised a list of 30 medications that should be avoided in nursing home residents regardless of diagnoses or dose and frequency of medication use. This list incorporated certain psychotropic medications, antihypertensives, oral hypoglycemic agents, nonsteroidal anti-inflammatory drugs (NSAIDs), and analgesic agents. In 1997, Beers published a revised and more comprehensive set of explicit criteria for potentially inappropriate drug use in ambulatory people aged 65 years or older.³⁵ The revised criteria were designed to be applicable to all adults aged 65 years or older regardless of their place of residence (community or nursing home) or level of frailty. The criteria divided potentially inappropriate drugs into three categories: drugs that generally should be avoided in older adults; doses, frequencies, or durations of specific therapies that vary from those generally accepted as appropriate use in elderly persons; and drugs to be avoided in combination with a specific co-morbidity. Beers' criteria were again updated in 2003.³⁶ The criteria specify PIMs both independent of diagnosis and condition (Table 1) and also by specific diagnosis and condition (Table 2). The new criteria included additions to the general list of inappropriate medications (eg, nitrofurantoin, doxazosin, and amiodarone). Fifteen medications and medication classes were removed from the 1997 list, eg, the use of beta-blockers (with exception of propranolol) in those with COPD, asthma, peripheral vascular disease and syncope or falls. The co-morbidity list in

Table 1 2002 Beers' criteria for potentially inappropriate medication use with a high severity rating in older adults: Independent of diagnosis or condition³⁶

Drug	Concern
Amitriptyline, chlordiazepoxide-amitriptyline, perphenazine-amitriptyline <i>Amphetamines and anorexic drugs</i>	Exhibits strong anticholinergic and sedation properties. Use is associated with dependence, hypertension, angina, and myocardial infarction; Amphetamines other than methylphenidate and anorexic drugs can also cause CNS side effects.
Amiodarone	Associated with QT interval prolongation, may provoke torsades de pointes, and lacks efficacy in the elderly.
<i>Antipsychotic medications:</i> mesoridazine, thioridazine	Have CNS and extrapyramidal side effects.
<i>Antihistamines and anticholinergic medications:</i> chlorpheniramine, diphenhydramine, hydroxyzine, cyproheptadine, promethazine, tripeleminamine, dexchlorpheniramine	Has potent anticholinergic properties and can cause sedation and confusion.
<i>Barbiturates:</i> all barbiturates ^a except phenobarbital	Are highly addictive and cause more adverse effects than most sedative or hypnotic drugs.
<i>Benzodiazepines (long-acting):</i> chlordiazepoxide, chlordiazepoxide-amitriptyline, clidinium-chlordiazepoxide, diazepam, quazepam, halazepam, chlorazepate	Exhibits long half-life, producing sedation and increasing incidence of falls and fractures.
<i>Benzodiazepines (short-acting):</i> Lorazepam (doses exceeding 3 mg), oxazepam (doses exceeding 60 mg), alprazolam (doses exceeding 2 mg), temazepam (doses exceeding 15 mg), triazolam (doses exceeding 0.125 mg)	Increased sensitivity at higher doses.
Chlorpropamide	Has a long half-life leading to possible prolonged hypoglycemia and can cause SIADH.
Desiccated thyroid	Has cardiac side effects concerns.
Disopyramide	Has the most potent negative inotropic properties compared to other antiarrhythmic drugs and exhibits significant anticholinergic side effects.
Fluoxetine (daily use)	Exhibits a long half-life and risk of producing excessive CNS stimulation, sleep disturbances, and agitation.
Flurazepam	Exhibits long half-life, producing sedation and increasing incidence of falls and fractures.
<i>Gastrointestinal antispasmodic drugs:</i> dicyclomine, hyoscyamine, propantheline, clidinium-chlordiazepoxide	Have strong anticholinergic side effects and questionable efficacy.
Guanethidine	Can cause orthostatic hypotension.
Guanadrel	Can cause orthostatic hypotension.
Indomethacin	Exhibits greatest CNS side effects compared to other NSAIDs.
Ketorolac	Immediate and long-term use should be avoided as older adults have a higher incidence of asymptomatic GI pathologic conditions.
Meperidine	May cause confusion and may lack effectiveness in doses commonly used.
Meprobamate	Exhibits highly addictive and sedating properties.
Methyldopa and methyldopa-hydrochlorothiazide	May cause bradycardia and exacerbate depression.
Mineral oil	Has potential for aspiration side effects.
<i>Muscle relaxants and antispasmodics:</i> methocarbamol, carisoprodol, chlorzoxazone, metaxalone, cyclobenzaprine, oxybutynin (not XL formulation)	Are poorly tolerated by elderly patients, exhibit anticholinergic side effects, sedation, and weakness; questionable effectiveness at doses tolerated by the elderly.
Nifedipine (short acting only)	Causes hypotension and constipation.
Nitrofurantoin	Has potential for renal impairment.
<i>NSAIDs (long-term use, longer half-life, non-COX selective):</i> naproxen, oxaprozin, piroxicam	Have the potential for produce GI bleeding, renal failure, high blood pressure, and heart failure.
Orphenadrine	Causes more sedation and anticholinergic side effects than safer alternatives.

(Continued)

Table 1 (Continued)

Drug	Concern
Pentazocine	Causes more CNS side effects more commonly than other narcotic drugs.
Stimulant laxatives (long-term use only): bisacodyl, cascara sagrada and neoloid ^b	May exacerbate bowel dysfunction.
Ticlopidine	No more effective than aspirin and may be considerably more toxic.
Trimethobenzamide	One of the least effective antiemetic drugs and exhibits extrapyramidal side effects.

Abbreviations: COX, cyclooxygenase; CNS, central nervous system; GI, gastrointestinal; NSAIDs, nonsteroidal anti-inflammatory drugs; SIADH, syndrome of inappropriate antidiuretic hormone secretion; XL, extended release; except when treating atrial arrhythmias.

Notes: ^aExcept when used to control seizures; ^bExcept in the presence of opiate analgesic use.

Table 2 2002 Beers' Criteria for potentially inappropriate medication use with a high severity rating in older adults: Considering diagnosis and condition. Modified from Reference 36

Disease or condition	Drug	Concern
Anorexia and malnutrition	CNS stimulants: Dextroamphetamine, methylphenidate, methamphetamine, pemolin, and fluoxetine	Concern due to appetite-suppressing effects.
Arrhythmias	TCA's (imipramine hydrochloride, doxepin hydrochloride, and amitriptyline hydrochloride)	Concern due to proarrhythmic effects and ability to produce QT interval changes.
Bladder outflow obstruction	Anticholinergics and antihistamines, GI antispasmodics, muscle relaxants, oxybutynin, flavoxate, anticholinergics, antidepressants, decongestants, and tolterodine	May decrease urinary flow, leading to urinary retention.
Blood clotting disorders or receiving anticoagulant therapy	Aspirin, NSAIDs, dipyridamole, ticlopidine, and clopidogrel	May prolong clotting time and elevate INR values or inhibit platelet aggregation, resulting in an increased potential for bleeding.
COPD	Long-acting benzodiazepines: chlorthalidone, chlorthalidone-amitriptyline, clonidine-chlorthalidone, diazepam, quazepam, halazepam, and chlorazepate; β -blockers: propranolol	CNS adverse effects. May induce respiratory depression. May exacerbate or cause respiratory depression.
Cognitive impairment	Barbiturates, anticholinergics, antispasmodics, and muscle Relaxants; CNS stimulants: dextroamphetamine, methylphenidate, methamphetamine, and pemolin	Concern due to CNS-altering effects.
Depression	Long-term benzodiazepine use. Sympatholytic agents: methyl dopa, reserpine, and guanethidine	May produce or exacerbate depression.
Gastric or duodenal ulcers	NSAIDs and aspirin (≥ 325 mg) (coxibs excluded)	May exacerbate existing ulcers or produce new/additional ulcers.
Heart failure	Disopyramide and high sodium content drugs (sodium and sodium salts [alginate bicarbonate, biphosphate, citrate, phosphate, salicylate, and sulfate])	Negative inotropic effect. Potential to promote fluid retention and exacerbation of heart failure.
Hypertension	Phenylpropanolamine hydrochloride ^a , pseudoephedrine; diet pills, and amphetamines	May produce elevation of blood pressure secondary to sympathomimetic activity.
Insomnia	Decongestants, theophylline, methylphenidate, MAOIs, and amphetamines	Concern due to CNS stimulant effects.
Parkinson disease	Metoclopramide, conventional antipsychotics, and tacrine	Concern due to their antidopaminergic/cholinergic effects.
Seizures or epilepsy	Clozapine, chlorpromazine, thioridazine, and thiothixene	May lower seizure thresholds.
Stress incontinence	α -blockers (doxazosin, prazosin, and terazosin), anticholinergics, TCA's (imipramine, doxepin, and amitriptyline), and long-acting benzodiazepines	May produce polyuria and worsening of incontinence.
Syncope or falls	Short- to intermediate-acting benzodiazepine and TCA's (imipramine, doxepin, and amitriptyline)	May produce ataxia, impaired psychomotor function, syncope, and additional falls.

Abbreviations: CNS, central nervous system; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; INR, international normalized ratio; MAOIs, monoamine oxidase inhibitors; NSAIDs, nonsteroidal anti-inflammatory drugs; SIADH, syndrome of inappropriate antidiuretic hormone secretion; SSRIs, selective serotonin reuptake inhibitors; TCA's, tricyclic antidepressants.

Notes: ^aRemoved from the market in 2001.

turn included new diagnoses such as depression, Parkinson's disease, cognitive impairment, and incontinence.

In the US, the Beers' criteria have become the most popular and accepted explicit tool used for evaluating PIM prescribing. In fact, many health plans and pharmacy benefit managers have adopted the Beers' criteria or a modification of the list to help identify and target elderly members at risk of ADEs associated with PIM prescribing. Beginning in 2006, the National Committee for Quality Assurance has included a Health Plan Employer Data and Information Set (HEDIS) performance measure for the managed care industry to use to evaluate the percentage of members aged 65 years or older who receive medications that should be avoided. The specifications for this HEDIS performance measure are based on the Beers criteria with some modification.^{37,38}

Numerous research studies have employed the Beers' criteria to evaluate PIM prescribing and ADEs in the inpatient setting. Using the most updated Beers' criteria, Gallagher and colleagues found that of the 597 admissions admitted to an Irish university teaching hospital, inappropriate prescribing occurred in 32% of elderly inpatients in which 24%, 6%, and 2% were taking one, two, or three inappropriate medications, respectively.³⁹ Forty-nine percent of patients with inappropriate prescriptions were admitted with ADEs from the inappropriate medication, and 16% of all admissions were associated with such adverse effects. In a US study, Rothberg found that of 493,971 hospitalized elderly, 49% received at least one inappropriate prescription and 6% received three or more. The most common inappropriate medications prescribed consisted of promethazine, diphenhydramine, and propoxyphene.⁸ However, controversy exists regarding exposure to PIMs and ADEs. In a study of 389 elderly inpatients, Page and Ruscin demonstrated that while 27.5% of inpatients received a drug listed on the Beers' criteria and 32% did experience an ADE, only 9.2% of ADEs were attributed to a Beers' criteria medication.⁴⁰ In fact, after controlling for covariates, prescription of a Beers' criteria medication was not significantly associated with experiencing an ADE, discharge to higher levels of care, or in-hospital mortality.

The use of a list of medications, such as the Beers' criteria, as a sole measurement for PIM prescribing has disadvantages. First, the inclusion of some drugs is subject to controversy, and insufficient evidence exists to support inclusion of some drugs presently on the Beers' medication list. Second, the prescription of drugs that should be avoided is a relatively minor problem when compared with other categories of inappropriate prescribing such as under- and over-use of medications, drug-drug interactions, drug

disease interactions, or drug duplication. The Beers' criteria do not address any of these facets. Third, the reliability of the process to generate such lists is not established. Fourth, while the Beers' criteria may be easy to use, they lack comprehensiveness, organization, and structure.

Improved prescribing in the elderly tool (IPET)

Referred to as the "Canadian Criteria", the IPET consists of a list of the 14 most prevalent prescription errors identified from a long list of inappropriate prescription instances drawn up by an expert Canadian Consensus Panel in 1997 (Table 3).⁴¹ The IPET was initially validated in a prospective study of acutely hospitalized elderly patients that demonstrated PIM prescribing in 12.5% of patients.⁴¹ However, little use of this instrument exists outside of Canada with the exception of one Irish study that found that 22% of acutely hospitalized elderly were taking at least one inappropriate prescription medication at the point of admission.⁴² Furthermore, as with the Beers' criteria, insufficient convincing evidence exists regarding IPET's efficacy to reduce ADR incidence, reduce excessive health resource utilization or decrease mortality. The IPET only cites 14 instances of inappropriate prescribing, three of which relate solely to TCAs, which are infrequently used in today's medical practice.

Table 3 The improving prescribing in the elderly tool (IPET). Modified with permission from Naugler and colleagues⁴¹

The following medications represent potentially inappropriate prescriptions in an elderly patient:

- β-blocker and chronic obstructive airways disease
- β-blocker and congestive heart failure
- Calcium channel blocker (excluding amlodipine and felodipine) and congestive heart failure
- Thiazide diuretic and gout
- Long half-life benzodiazepines (chlordiazepoxide, chlorazepate, diazepam, flurazepam, clonazepam, nitrazepam)
- Tricyclic antidepressant and glaucoma
- Tricyclic antidepressant and heart block
- Tricyclic antidepressant with active metabolites (imipramine, doxepin, or amitriptyline)
- Methylphenidate for depression
- Nonsteroidal anti-inflammatory drugs^a and peptic ulcer disease
- Nonsteroidal anti-inflammatory drugs and hypertension
- Long term use of nonsteroidal anti-inflammatory drugs for osteoarthritis
- Anticholinergic drugs to treat side effects of antipsychotic medications
- Long term diphenoxylate to treat diarrhea

Notes: ^aConsider acetylsalicylic acid as a nonsteroidal anti-inflammatory drug only if the dose is greater than 1300 mg/day.

Furthermore, the IPET is outdated as it recommends against the use of beta-blockers in heart failure contrary to current guidelines and published evidence. Finally, IPET is heavily weighted towards cardiovascular drug use, psychotropic drug use, and NSAID use and is not organized in any particular order or structure.

Screening tool of older persons (STOPP)

Developed by a multidisciplinary team of Irish geriatricians, pharmacists, pharmacologists, and primary care physicians, the STOPP incorporates commonly encountered instances of PIM prescribing in older adults that include drug–drug and drug–disease interactions, drugs that adversely affect older patients at risk of falls, and duplicate drug class prescriptions (Table 4).⁴³ Its criteria are arranged according to relevant

physiological systems for ease of use, and each criterion is accompanied by a concise explanation as to why the prescription is potentially inappropriate.⁴³

The performance of the STOPP and Beers criteria has been evaluated for detecting PIM prescribing and related ADRs in 715 older patients admitted to a university teaching hospital in Ireland.⁴⁴ The STOPP identified 336 PIMs affecting 35% of patients, one-third of whom presented with an associated ADE, while the Beers' criteria identified 226 PIMs affecting 25% of patients, of whom 43% presented with an associated ADE. The STOPP-related PIMs contributed to 11.5% of all admissions, while the Beers' criteria-related PIMs contributed to significantly fewer admissions (6%). The most common PIMs identified by STOPP included use of long-acting benzodiazepines, TCAs with clear-cut

Table 4 STOPP: screening tool of older persons' potentially inappropriate prescriptions^{a,43,44}

System	Drug or drug class	Conditions and concerns (<i>in italics</i>)
Cardiovascular	Aspirin	<ul style="list-style-type: none"> • In combination with warfarin without a histamine type 2 receptor antagonist (except cimetidine due to warfarin interaction) or PPI due to <i>high risk of GI bleeding</i>. • With a past history of PUD without a histamine 2 receptor antagonist due to <i>risk of bleeding</i>. • In doses exceeding 150 mg/day due to <i>increased bleeding risk and lack of evidence for increased efficacy</i>. • With no history of coronary, cerebral, or peripheral vascular symptoms or occlusive event as aspirin is <i>not indicated</i>. • To treat dizziness not clearly attributable to cerebrovascular disease as aspirin is <i>not indicated</i>. • With concurrent bleeding disorder due to <i>high risk of bleeding</i>.
	β-blockers	<ul style="list-style-type: none"> • With COPD due to <i>risk of increased bronchospasm</i>. • In combination with verapamil due to <i>increased risk of symptomatic heart block</i>.
	Calcium channel blockers	<ul style="list-style-type: none"> • Use of verapamil or diltiazem in patients with NYHA class III or IV heart failure due to <i>increased risk of toxicity</i>. • With chronic constipation as this <i>may exacerbate constipation</i>.
	Clopidogrel	<ul style="list-style-type: none"> • With concurrent bleeding disorder due to <i>high risk of bleeding</i>.
	Digoxin	<ul style="list-style-type: none"> • For long term use in doses > 125 mcg/day with impaired renal function (GFR < 50 ml/min) due to <i>increased risk of toxicity</i>.
	Dipyridamole	<ul style="list-style-type: none"> • As monotherapy for cardiovascular secondary prevention due to <i>lack of evidence</i>. • With concurrent bleeding disorder due to <i>high risk of bleeding</i>.
	Loop diuretics	<ul style="list-style-type: none"> • For dependent ankle edema only (ie, no clinical signs of heart failure) due to <i>lack of evidence</i> and <i>compression hosiery usually more appropriate</i>.
	Thiazide diuretics	<ul style="list-style-type: none"> • With a history of gout as this <i>may exacerbate gout</i>.
	Warfarin	<ul style="list-style-type: none"> • In combination with aspirin without a histamine type 2 receptor antagonist (except cimetidine due to warfarin interaction) or PPI due to <i>high risk of GI bleeding</i>. • For 1st uncomplicated pulmonary embolism for longer than 12 months duration due to <i>lack of proven benefit</i>. • With concurrent bleeding disorder due to <i>high risk of bleeding</i>.

(Continued)

Table 4 (Continued)

System	Drug or drug class	Conditions and concerns (<i>in italics</i>)
CNS	Anticholinergics	<ul style="list-style-type: none"> To treat extra-pyramidal side effects of neuroleptic medications due to <i>risk of anticholinergic toxicity</i>. Prolonged use (> 1 week) due to <i>risk of sedation and anticholinergic side effects</i>.
	Antihistamines (first generation): diphenhydramine, chlorpheniramine, cyclizine, promethazine	
	Benzodiazepines (long-acting): chlordiazepoxide, flurazepam, nitrazepam, chlorazepate	<ul style="list-style-type: none"> Avoid due to <i>high risk of prolonged sedation, confusion, impaired balance, and falls</i>.
	Benzodiazepines (with long metabolites): diazepam	<ul style="list-style-type: none"> Avoid due to <i>high risk of prolonged sedation, confusion, impaired balance, and falls</i>.
	Neuroleptics	<ul style="list-style-type: none"> With long term use of > 1 month due to <i>high risk of confusion, hypotension, extra-pyramidal side effects, and falls</i>. With long term use of > 1 month in patients with Parkinson's disease due to <i>risk worsening, extra-pyramidal symptoms</i>.
	Phenothiazines	<ul style="list-style-type: none"> In patients with epilepsy as phenothiazines may <i>lower seizure threshold</i>.
	SSRIs	<ul style="list-style-type: none"> With a history of clinically significant hyponatremia defined as noni-atrogenic sodium < 130 meq/L within the previous two months.
	TCA's	<ul style="list-style-type: none"> With dementia due to <i>risk of worsening cognitive impairment</i>. With glaucoma as TCAs may <i>exacerbate glaucoma</i>. With cardiac conduction abnormalities due to TCAs' <i>pro-arrhythmic effects</i>. With constipation as TCAs may <i>worsen constipation</i>. With opiate or calcium channel blockers as TCAs may <i>worsen constipation</i>. With prostatism or prior history of urinary retention due to <i>increased risk of urinary retention</i>.
		<ul style="list-style-type: none"> With chronic constipation due to <i>risk of constipation exacerbation</i>.
		<ul style="list-style-type: none"> For treatment of diarrhea of unknown cause due to <i>risk of delayed diagnosis, possible exacerbation of constipation with overflow diarrhea, precipitation of toxic megacolon in inflammatory bowel disease, and delayed recovery in unrecognized gastroenteritis</i>.
GI	Anticholinergic antispasmodic drugs	<ul style="list-style-type: none"> For treatment of severe infective gastroenteritis (ie, bloody diarrhea, high fever or severe systemic toxicity) due to <i>risk of exacerbation or protraction of infection</i>.
	Diphenoxylate, loperamide, or codeine phosphate	
Respiratory	Prochlorperazine, metoclopramide	<ul style="list-style-type: none"> With Parkinsonism due to <i>risk of exacerbating Parkinsonism</i>.
	PPIs	<ul style="list-style-type: none"> For PUD at full therapeutic dosage for > 8 weeks.
	Corticosteroids (systemic)	<ul style="list-style-type: none"> For maintenance therapy in moderate to severe COPD instead of inhaled corticosteroids due to <i>unnecessary exposure to long-term side effects of systemic steroids</i>.
	Ipratropium (nebulized)	<ul style="list-style-type: none"> In patients with glaucoma due to <i>possible glaucoma exacerbation</i>.
	Theophylline	<ul style="list-style-type: none"> As monotherapy for COPD as <i>more safer, more effective alternatives exist and the risk of adverse effects due to narrow therapeutic index</i>.
Musculoskeletal	NSAIDs	<ul style="list-style-type: none"> With a history of PUD or GI bleeding, unless with concurrent histamine type 2 receptor blocker, PPI or misoprostol due to <i>risk of PUD relapse</i>. With moderate (160/100–179/109 mmHg) or severe (> 180/110 mmHg) hypertension due to <i>risk of exacerbation of hypertension</i>. With heart failure due to <i>risk of heart failure exacerbation</i>. With warfarin concomitantly due to <i>risk of GI bleeding</i>. With chronic renal failure (GFR 20–50 ml/min) due to <i>risk of deterioration in renal function</i>. With long-term use (> 3 months) for relief of mild joint pain in osteoarthritis as <i>simple analgesics preferable and usually as effective for pain relief</i>.

(Continued)

Table 4 (Continued)

System	Drug or drug class	Conditions and concerns (<i>in italics</i>)
Urogenital	Colchicine	<ul style="list-style-type: none"> For chronic treatment of gout where there is no contraindication to allopurinol as <i>allopurinol is considered first choice for prophylaxis in gout.</i>
	Corticosteroids	<ul style="list-style-type: none"> For chronic treatment of gout where there is no contraindication to allopurinol as <i>allopurinol is considered first choice for prophylaxis in gout.</i> As long-term (>3 months) monotherapy for rheumatoid arthritis or osteoarthritis due to <i>risk of major systemic corticosteroid side-effects.</i>
	Antimuscarinic drugs	<ul style="list-style-type: none"> With dementia due to <i>risk of increased confusion and agitation.</i> With chronic glaucoma due to <i>risk of acute exacerbation of glaucoma.</i> With chronic constipation due to <i>risk of exacerbation of constipation.</i> With chronic prostatism due to <i>risk of urinary retention.</i>
	α -blockers	<ul style="list-style-type: none"> In males with frequent incontinence (ie, one or more episodes of incontinence daily) due to <i>risk of urinary frequency and worsening incontinence.</i> With long term urinary catheter in situ (ie, more than two months) as <i>drug is not indicated.</i>
Endocrine	Chlorpropamide or glibenclamide	<ul style="list-style-type: none"> With type 2 diabetes due to <i>risk of prolonged hypoglycemia.</i>
	β -blockers	<ul style="list-style-type: none"> In those with diabetes mellitus and frequent hypoglycemic episodes (ie, ≥ 1 episodes/month) due to <i>risk of masking hypoglycemic symptoms.</i>
	Estrogen	<ul style="list-style-type: none"> With a history of breast cancer or VTE due to <i>increased risk of recurrence.</i> Without progestogen in patients with intact uterus due to <i>risk of endometrial cancer.</i>
Drug issues		
Analgesic drugs	Opiates	<ul style="list-style-type: none"> Use of long-term power opiates (eg, morphine or fentanyl) as first line therapy for mild-moderate pain as <i>WHO analgesic ladder is not observed.</i> Regular use for more than two weeks in those with chronic constipation without use of laxatives due to <i>risk of severe constipation.</i> Long-term use in those with dementia unless indicated for palliative care or management of moderate-severe chronic pain syndrome due to <i>risk of exacerbation of cognitive impairment.</i>
	Duplicate drug class	<ul style="list-style-type: none"> Use of any two concurrent duplicate medications as <i>optimization of monotherapy within a single drug class should be observed prior to considering a new drug class.</i>
Drugs adversely affecting those prone to falls ^b	ACE inhibitors	<ul style="list-style-type: none"> Use of any two concurrent duplicate medications as <i>optimization of monotherapy within a single drug class should be observed prior to considering a new drug class.</i>
	Loop diuretics	
	NSAIDs	
	Opiates	
	SSRIs	
Drugs adversely affecting those prone to falls ^b	Antihistamines (first generation)	<ul style="list-style-type: none"> <i>May cause sedation and impair sensorium.</i>
	Benzodiazepines	<ul style="list-style-type: none"> <i>May cause sedation and impair sensorium.</i>
	Neuroleptic drugs	<ul style="list-style-type: none"> <i>May cause gait dyspraxia and Parkinsonism.</i>
	Opiates	<ul style="list-style-type: none"> Long-term use in those with recurrent falls due to <i>risk of drowsiness, postural hypotension, and vertigo.</i>
	Vasodilators (known to cause hypotension)	<ul style="list-style-type: none"> In those with persistent postural hypotension (ie, recurrent >20 mmHg drop in systolic blood pressure) due to <i>risk of syncope and falls.</i>

Abbreviations: ACE, angiotensin-converting enzyme; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; NYHA, New York Heart Association; NSAIDs, nonsteroidal anti-inflammatory drugs; PPIs, proton pump inhibitors; PUD, peptic ulcer disease; SSRIs, selective serotonin re-uptake inhibitors; TCAs, tricyclic antidepressants; VTE, venous thromboembolism; WHO, World Health Organization.

Notes: ^aThe following prescription drugs are potentially inappropriate in persons ages ≥ 65 years of age; ^b ≥ 1 fall in the past three months.

contraindications, first generation antihistamines, vasodilator drugs known to cause hypotension in patients with persistent postural hypotension, inappropriate use of NSAIDs and opiates, and duplicate drug class prescriptions such as two angiotensin converting enzyme inhibitors, two NSAIDs, two selective serotonin reuptake inhibitors or dual antiplatelet therapy without indication. The authors concluded that compared to the Beers' criteria the STOPP criteria are more sensitive in identifying patients liable to suffer harm from an ADE because of PIM prescribing.

The advantages of the STOPP consist of good inter-rater reliability, inclusion of both American and European medications, organization and structure based physiological systems, and short time to complete (~3 minutes). However, this European tool needs to be evaluated in additional studies and in other settings.

Medication appropriateness index (MAI)

Initially developed by Dr Joseph Hanlon and colleagues, the MAI is a validated measure of prescribing appropriateness that assesses ten elements of prescribing: indication, effectiveness, dose, correct directions, practical directions, drug–drug interactions, drug–disease interactions, duplication, duration, and cost.⁴⁵ While this implicit approach requires clinical judgment to assess criteria, the index has operational definitions and explicit instructions, which standardize the rating process. The ratings generate a weighted score that serves as a summary measure of prescribing appropriateness ranging from 0 to 18 (0 = no item inappropriate; 18 = all items inappropriate). Three components of the MAI (indication, effectiveness, and duplication) can be used to detect unnecessary polypharmacy and PIM prescribing.^{17,46}

In an evaluation of 11 Veterans Affairs Medical Centers involving 397 frail elderly inpatients, Hanlon and colleagues found that 92% of subjects had at least one drug with one or more inappropriate ratings. The most common problems involved expensive drugs (70%), impractical directions (55.2%), and incorrect dosages (50.9%).⁶ The most prevalent medication classes with appropriateness concerns consisted of gastric (50.6%), cardiovascular (47.6%), and central nervous system (23.9%) agents. In a similar inpatient population, Hajjar and colleagues found that 44% of frail elderly inpatients had at least one unnecessary medication at discharge.¹⁷ From their analysis, the factors most commonly associated with unnecessary drug prescribing consisted of hypertension diagnosis, multiple prescribers, and nine or more medications.

The MAI as a tool to evaluate PIM prescribing has major advantages: it has been tested in both the inpatient

and ambulatory settings, exhibits excellent intra-rater and inter-rater reliability, and has face and content validity. It addresses multiple components of prescribing appropriateness, and can be applied to every medication in the context of patient-specific characteristics. However, the tool is more time-consuming to complete (~10 minutes per drug assessed) and does not assess under-prescribing (untreated indications).⁴⁶ Most studies using the MAI have been performed in a single setting, with groups of elderly veterans from the Veterans Affairs Medical Center in Durham, North Carolina. As with other tools developed to date, the index needs to be validated in other populations and settings before being used universally.

Strategic approaches to curtailing PIM prescribing

Conceptually, PIM prescribing in the inpatient setting is a multi-faceted function of the patient, prescriber, and environment. First, the clinical needs of the patient must be the primary determinant of prescribing decisions. Appropriate prescribing should aim to promote the use of evidence-based therapies while minimizing the use of medications for which there is no clinical need, questionable evidence, or duplication. The patient's perceptions and preferences should also be considered. Second, prescribing is done mainly by providers who use their own clinical experience and attitudes in making medication decisions. Factors that contribute to PIM prescribing include inadequate training in geriatric pharmacotherapy as well as the absence of communication between providers practicing in different settings, or between specialists and the primary care provider. Finally, the environment in which the prescriber operates can affect prescribing decisions. Unfortunately, the acute care setting does not encourage review of chronic and preventive medications. Furthermore, the inpatient environment may lack the technological infrastructure to share information relating to drugs during transitions of care, which ultimately compromises quality.

With this in mind, several strategic approaches exist to potentially minimize PIM prescribing. The question surrounding which tool to use to measure quality of prescribing remains controversial. Quality measures are often chosen not only because of the clinical importance of the construct they measure but also their ease of use. In particular, drugs-to-avoid criteria have been a popular tool for research, in part due to their easy applicability to administrative databases. Although easy-to-administer measures such as drugs-to-avoid criteria (eg, Beers' criteria) capture useful elements of prescribing quality, that the relative ease of these metrics

creates an immediate danger that they will drive quality assessment and improvements efforts rather than vice versa. In fact, significant discordance exists between the MAI and Beers' criteria when using these tools to evaluate drug prescribing quality in similar populations.⁴⁷ Furthermore, when prescribing, one must take into account the patient as a whole, including his or her life expectancy and quality of life within a social and economical environment, select essential medications, and avoid drugs with a poorer benefit-to-risk ratio. Unfortunately, explicit prescribing criteria may force the prescriber to ignore these considerations by prescribing at the bedside according to inflexible, rigid guidelines. Therefore, based on these observations, because using a single tool may fail to capture the overall quality of a patient's medication regimen, it would seem prudent to consider employing multiple tools and multifaceted perspectives to capture the range of quality problems that may be present in medication prescribing.

While primarily documented in the ambulatory setting, additional strategies for hospital settings consist of using a computerized decision support system, implementing didactic educational programs within the health system, utilizing clinical pharmacist expertise on clinical rounds or for prospective medication review, and considering a comprehensive geriatric evaluation and management (GEM) care approach.^{5,48–56} This latter approach consists of a multidisciplinary team, which may include a geriatrician and other health care providers with specialized geriatric training (eg, nurses, pharmacists, dietitians, social workers, and psychologists). Data from the inpatient setting suggest that employing a GEM care team can lower potential drug-drug interactions and the number of unnecessarily prescribed drugs from admission to discharge, as well as decrease the time to discharge.^{5,52–54} Finally, infrastructure and hospital policies to provide medication reconciliation on admission and at discharge are crucial in response to medication discrepancies within the inpatient setting documented as problematic. Coleman and colleagues found that 14% of older community-dwelling patients experienced post-hospital medication discrepancies within two weeks of discharge, and that half of those discrepancies were system-related.¹⁶ Presently, medication reconciliation is included in the Joint Commission's National Patient Safety Goals. Goal 8 states that hospitals must "accurately and completely reconcile patient medications across the continuum of care."⁵⁷ In order to prevent fragmentation of care from the inpatient to the outpatient setting, clinical pharmacists and nurses have served as potential medication transition coordinators and discharge advocates. Data from two studies suggest that

such an approach can lower the rate of hospital readmission and emergency department visits.^{50,58}

Summary and future concerns

The prescribing of medications is a fundamental component of the care of the elderly, and the optimization of drug prescribing has become an important public health concern. The inpatient setting can be particularly hazardous regarding ADEs due to the problem of multiple prescribers, medication reconciliation issues, and poor communication between outpatient and inpatient providers. While tools are available to identify PIM prescribing and potential strategies exist to curtail the problem, several fundamental issues still exist. First, from an interventional and health care research perspective, even though data provide useful insights into the effectiveness of different approaches, the effect on important health outcomes and health care costs still needs to be evaluated. Second, despite substantial resource dedication to developing and testing the effectiveness of interventions to improve prescribing, widespread diffusion of successful methods has not yet been achieved. It also seems that our current culture, from the perspective of patients and prescribers, relies too heavily on pharmacological interventions to address medical problems. The use of medications is often the first and only intervention sought, when other proven interventions, such as psychotherapy for behavioral and mental health issues, may be appropriate. Also, to fully address appropriateness of prescribing, not only should the use of inappropriate medications be avoided, but the use of indicated and beneficial medications should be encouraged. In this instance, evidence-based criteria, such as the START (Screening Tool to Alert doctors to Right Treatment) criteria should compliment assessments.⁵⁹ Finally, the responsibility of appropriate prescribing should no longer fall solely on the shoulders of physician prescriber. Rather the responsibility should be shared across the multidisciplinary continuum of care with all health care professionals who provide care for the older adult.

Disclosures

The authors report no conflicts of interest in this work.

References

1. Institute of Medicine. *To Err Is Human: Building A Safer Health System*. Washington, DC: National Academies Press; 1999.
2. Gallagher P, Barry P, O'Mahony D. Inappropriate prescribing in the elderly. *J Clin Pharm Ther*. 2007;32(2):113–121.
3. Laroche ML, Charnes JP, Nouaille Y, et al. Is inappropriate medication use a major cause of adverse drug reactions in the elderly? *Br J Clin Pharmacol*. 2007;63(2):177–186.

4. Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. *JAMA*. 2008;300(24):2867–2878.
5. Spinewine A, Schmadher KE, Barber N, et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? *Lancet*. 2007;370(9582):173–184.
6. Hanlon JT, Artz MB, Pieper CF, et al. Inappropriate medication use among frail elderly inpatients. *Ann Pharmacother*. 2004;38(1):9–14.
7. Onder G, Landi F, Cesari M, et al. Inappropriate medication use among hospitalized older adults in Italy: results from the Italian Group of Pharmacoepidemiology in the Elderly. *Eur J Clin Pharmacol*. 2003;59(2):157–162.
8. Rothberg MB, Pekow PS, Liu F, et al. Potentially inappropriate medication use in hospitalized elders. *J Hosp Med*. 2008;3(2):91–102.
9. Agency for Health care Research and Quality. HCUP Facts and Figures, 2006: Statistics on Hospital-based Care in the United States. Available from: http://www.hcup-us.ahrq.gov/reports/factsandfigures/HAR_2006.pdf. Accessed December 14, 2009.
10. Edwards RF, Harrison TM, Davis SM. Potentially inappropriate medication use among frail elderly inpatients. *Consult Pharmacist*. 2003;18(1):37–42.
11. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. *N Engl J Med*. 2009;360(14):1418–1428.
12. Creditor MC. Hazards of hospitalization of the elderly. *Ann Intern Med*. 1993;118(3):219–223.
13. Friedman SM, Mendelson DA, Bingham KW, McCann RM. Hazards of hospitalization: residence prior to admission predicts outcomes. *Gerontologist*. 2008;48(4):537–541.
14. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. *N Engl J Med*. 2003;348(16):1556–1564.
15. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA*. 1998;279(15):1200–1205.
16. Coleman EA, Smith JD, Raha D, Min SJ. Posthospital medication discrepancies: prevalence and contributing factors. *Arch Intern Med*. 2005;165(16):1842–1847.
17. Hajjar ER, Hanlon JT, Sloane RJ, et al. Unnecessary drug use in frail older people at hospital discharge. *J Am Geriatr Soc*. 2005;53(9):1518–1523.
18. Bates DW, Miller EB, Cullen DJ, et al. Patient risk factors for adverse drug events in hospitalized patients. ADE Prevention Study Group. *Arch Intern Med*. 1999;159(21):2553–2560.
19. Carey IM, De Wilde S, Harris T, et al. What factors predict potentially inappropriate primary care prescribing in older people? Analysis of UK primary care patient record database. *Drugs Aging*. 2008;25(8):693–706.
20. Evans RS, Lloyd JF, Stoddard GJ, et al. Risk factors for adverse drug events: a 10-year analysis. *Ann Pharmacother*. 2005;39(7–8):1161–1168.
21. Kanjanarat P, Winterstein AG, Johns TE, et al. Nature of preventable adverse drug events in hospitals: a literature review. *Am J Health Syst Pharm*. 2003;60(17):1750–1759.
22. Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. *Exp Gerontol*. 2003;38(8):843–853.
23. Kinirons MT, Crome P. Clinical pharmacokinetic considerations in the elderly. An update. *Clin Pharmacokinet*. 1997;33(4):302–312.
24. El Desoky ES. Pharmacokinetic-pharmacodynamic crisis in the elderly. *Am J Ther*. 2007;14(5):488–498.
25. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. *Am J Geriatr Pharmacother*. 2007;5(4):314–316.
26. Goldberg RM, Mabey J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. *Am J Emerg Med*. 1996;14(5):447–450.
27. Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. *Arch Intern Med*. 1990;150(4):841–845.
28. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. *N Engl J Med*. 2009;360(3):225–235.
29. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. *Ann Intern Med*. 2007;146(11):775–786.
30. Rochon PA, Normand SL, Gomes T, et al. Antipsychotic therapy and short-term serious events in older adults with dementia. *Arch Intern Med*. 2008;168(10):1090–1096.
31. Robert Wood Johnson Foundation. Partnership For Solutions, Better Living for People with Chronic Conditions [homepage on the internet]. Disease management and multiple chronic conditions. 2006. Availability from www.partnershipforsolutions.org/DMS/files/DMfactsheet21final.pdf. Accessed December 14, 2009.
32. Merrill CT, Elixhauser A. *Hospitalization in the United States*. HCUP Fact Book No. 6. Rockville (MD): Agency for Health care Research and Quality; 2002.
33. Page RL 2nd, Strongin K, Millis R, et al. Medicare beneficiaries with mild to moderate heart failure see 15–23 different providers annually (Abstract #5922). *Circulation*. 2007;118(18):S1030.
34. Beers MH, Ouslander JG, Rollinger I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. *Arch Intern Med*. 1991;151(9):1825–1832.
35. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. *Arch Intern Med*. 1997;157(14):1531–1536.
36. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. *Arch Intern Med*. 2003;163(22):2716–2724.
37. National Committee for Quality Assurance (NCQA). HEDIS® 2006 Technical Specifications. Item #10284-100-06. Washington, DC, 2005.
38. National Committee for Quality Assurance (NCQA). HEDIS® 2007 Technical Specifications. Item #10284-100-06. Washington, DC, 2006.
39. Gallagher PF, Barry PJ, Ryan C, et al. Inappropriate prescribing in an acutely ill population of elderly patients as determined by Beers' Criteria. *Age Ageing*. 2008;37(1):96–101.
40. Page RL 2nd, Ruscin JM. The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use. *Am J Geriatr Pharmacother*. 2006;4(4):297–305.
41. Naugler CT, Brymer C, Stolee P, Arcese ZA. Development and validation of an improving prescribing in the elderly tool. *Can J Clin Pharmacol*. 2000;7(2):103–107.
42. Barry PJ, O'Keefe N, O'Connor KA, O'Mahony D. Inappropriate prescribing in the elderly: a comparison of the Beers criteria and the improved prescribing in the elderly tool (IPET) in acutely ill elderly hospitalized patients. *J Clin Pharm Ther*. 2006;31(6):617–626.
43. Gallagher P, Ryan C, Byrne S, et al. STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. *Int J Clin Pharmacol Ther*. 2008;46(2):72–83.
44. Gallagher P, O'Mahony D. STOPP (Screening Tool of Older Persons' potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers' criteria. *Age Ageing*. 2008;37(6):673–679.
45. Hanlon JT, Schmadher KE, Samsa GP, et al. A method for assessing drug therapy appropriateness. *J Clin Epidemiol*. 1992;45(10):1045–1051.
46. Samsa GP, Hanlon JT, Schmadher KE, et al. A summated score for the medication appropriateness index: development and assessment of clinimetric properties including content validity. *J Clin Epidemiol*. 1994;47(8):891–896.
47. Steinman MA, Rosenthal GE, Landefeld CS, et al. Conflicts and concordance between measures of medication prescribing quality. *Med Care*. 2007;45(1):95–99.

48. Agostini JV, Concato J, Inouye SK. Improving sedative-hypnotic prescribing in older hospitalized patients: provider-perceived benefits and barriers of a computer-based reminder. *J Gen Intern Med*. 2008;23 Suppl 1:32–36.
49. Brekke M, Rognstad S, Straand J, et al. Pharmacologically inappropriate prescriptions for elderly patients in general practice: How common? Baseline data from The Prescription Peer Academic Detailing (Rx-PAD) study. *Scand J Prim Health Care*. 2008;26(2):80–85.
50. Crotty M, Rowett D, Spurling L, et al. Does the addition of a pharmacist transition coordinator improve evidence-based medication management and health outcomes in older adults moving from the hospital to a long-term care facility? Results of a randomized, controlled trial. *Am J Geriatr Pharmacother*. 2004;2(4):257–264.
51. Hanlon JT, Weinberger M, Samsa GP, et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. *Am J Med*. 1996;100(4):428–437.
52. Saltvedt I, Spigset O, Ruths S, et al. Patterns of drug prescription in a geriatric evaluation and management unit as compared with the general medical wards: a randomised study. *Eur J Clin Pharmacol*. 2005;61(12):921–928.
53. Schmader KE, Hanlon JT, Pieper CF, et al. Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly. *Am J Med*. 2004;116(6):394–401.
54. Spinewine A, Swine C, Dhillon S, et al. Effect of a collaborative approach on the quality of prescribing for geriatric inpatients: a randomized, controlled trial. *J Am Geriatr Soc*. 2007;55(5):658–665.
55. Tamblyn R, Huang A, Perreault R, et al. The medical office of the 21st century (MOXXI): effectiveness of computerized decision-making support in reducing inappropriate prescribing in primary care. *CMAJ*. 2003;169(6):549–556.
56. Yourman L, Concato J, Agostini JV. Use of computer decision support interventions to improve medication prescribing in older adults: a systematic review. *Am J Geriatr Pharmacother*. 2008;6(2):119–129.
57. Young B. Medication reconciliation matters. *Medsurg Nurs*. 2008;17(5):332–336.
58. Jack BW, Chetty VK, Anthony D, et al. A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. *Ann Intern Med*. 2009;150(3):178–187.
59. Ryan C, O'Mahony D, Byrne S. Application of STOPP and START criteria: interrater reliability among pharmacists. *Ann Pharmacother*. 2009;43(7):1239–1244.

Clinical Interventions in Aging

Publish your work in this journal

Clinical Interventions in Aging is an international, peer-reviewed journal focusing on evidence-based reports on the value or lack thereof of treatments intended to prevent or delay the onset of maladaptive correlates of aging in human beings. This journal is indexed on PubMed Central, MedLine, the American Chemical Society's 'Chemical Abstracts Ser-

Submit your manuscript here: <http://www.dovepress.com/clinical-interventions-in-aging-journal>

vice' (CAS), Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress